Sutro Biopharma (STRO) Net Equity Issued and Repurchased (2019 - 2024)

Sutro Biopharma (STRO) posted Net Equity Issued and Repurchased of -$50.0 million for Q2 2024, down 134.92% sequentially from $143.2 million in Q4 2020.

Sutro Biopharma (STRO) Net Equity Issued and Repurchased (2019 - 2024) Analysis & Trends

Sutro Biopharma has reported Net Equity Issued and Repurchased for 3 years, with the latest figure at -$50.0 million in Q2 2024.

  • Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to -$50.0 million in Q2 2024, while the trailing twelve-month figure through Sep 2025 was -$50.0 million (down 145.47% YoY) and the FY2024 annual result came in at $25.0 million, changed N/A from the prior year.
  • Net Equity Issued and Repurchased retreated to -$50.0 million in Q2 2024 per STRO's latest filing, from $143.2 million in the prior quarter.
  • Over five years, Net Equity Issued and Repurchased peaked at $143.2 million in Q4 2020 and troughed at -$50.0 million in Q2 2024.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Equity Issued and Repurchased (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 49.20 Mn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn -
4 Revolution Medicines 43.64 Bn 43.64 Bn - 141.90 Mn
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn -
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn -
7 Royalty Pharma 33.72 Bn 35.84 Bn - -
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn -
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn -
10 Sutro Biopharma 339.58 Mn 175.24 Mn - -

Historic Data

Download Data
DateValue
Jun 30, 2024 -50.00 Mn
Jun 30, 2024 -50.00 Mn
Dec 31, 2020 143.17 Mn
Dec 31, 2020 143.17 Mn
Sep 30, 2020 16.80 Mn
Sep 30, 2020 16.80 Mn
Dec 31, 2019 -327,000.00
Dec 31, 2019 -327,000.00